Pharmaceuticals - Community Register


Community register of medicinal products for human use


Product information

Invented name: Sirturo   
Auth. number : EU/1/13/901
INN : bedaquiline
Orphan status based on designation EU/3/05/314 added on 07/03/2014
ATC: Anatomical main group: J - General antiinfectives for systemic use
Therapeutic subgroup: J04 - Antimycobacterials
Pharmacological subgroup: J04A - Drugs for treatment of tuberculosis
Chemical subgroup: J04AK - Other drugs for treatment of tuberculosis
Chemical substance: J04AK05 - Bedaquiline
(See WHO ATC Index)
Indication: SIRTURO is indicated for use as part of an appropriate combination regimen for pulmonary multidrug resistant tuberculosis (MDR TB) in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Marketing Authorisation Holder: Janssen-Cilag International NV
Turnhoutseweg 30, B-2340 Beerse, België

  EPAR and active package presentations

Package presentations

Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register.


European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
07/03/2014 Centralised - Authorisation EMEA/H/C/2614 (2014)1616 of 05/03/2014
27/03/2014 Centralised - Notification EMEA/H/C/2614/N/1